Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy
Molecular Pain · 2025
DOI: 10.1177/17448069251314857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2025. Verfasst von Salvador Sierra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. Hauptthemen laut MEDLINE: Paclitaxel, Up-Regulation, Spinal Cord, Peripheral Nervous System Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIMH NIH HHS, National Institute of Mental Health.
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and severe side effect affecting cancer patients undergoing paclitaxel treatment. Growing evidence underscores the pivotal role of calcitonin-related peptide (CGRP) in the development of CIPN. Repeated administration of paclitaxel induces alterations in CGRP release from sensory neurons within the dorsal root ganglia (DRG). The density of the CGRP receptor is most prominent in the dorsal horn of the spinal cord, where it overlaps with the distribution of CGRP. However, the impact of chemotherapy treatment on expression of the CGRP receptor in the spinal cord remains unclear, as well as the potential therapeutic benefits of a CGRP receptor antagonist in an animal model of CIPN. Using a mouse model of paclitaxel-induced mechanical hypersensitivity, we show upregulation of Calcitonin receptor-like receptor ( Calcrl) mRNA expression in the spinal cord, an event that occurred in association with upregulation of the H3K4 methyltransferase MLL2. This effect of repeated paclitaxel administration was also linked to an increase in the recruitment of MLL2, thereby enhancing levels of the active mark H3K4me2 at the Calcrl promoter. Furthermore, administration of the CGRP receptor antagonist BIBN4096 mitigated mechanical and cold hypersensitivity in paclitaxel-treated mice. Together, these observations suggest the CGRP receptor in the spinal cord as a potential target for reducing paclitaxel-induced neuropathic pain in animal models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
- Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
- Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
- Department of Biostatistics, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
ORCID-Profile: Javier Gonzalez-Maeso
Förderung
- NIMH NIH HHS
- National Institute of Mental Health
Zitieren
APA
Sierra, S., Herz, S. M., On, D., Dozmorov, M. G., Damaj, M. I., & Gonzalez-Maeso, J. (2025). Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy. Molecular Pain. https://doi.org/10.1177/17448069251314857
Vancouver
Sierra S, Herz SM, On D, Dozmorov MG, Damaj MI, Gonzalez-Maeso J. Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy. Molecular Pain. 2025. doi:10.1177/17448069251314857
BibTeX
@article{Sierra2025,
author = {Sierra, Salvador and Herz, Sara M and On, Doan and Dozmorov, Mikhail G and Damaj, M Imad and Gonzalez-Maeso, Javier},
title = {Upregulation of the neuropeptide receptor calcitonin receptor-like in the spinal cord via MLL2 in a mouse model of paclitaxel-induced peripheral neuropathy},
journal = {Molecular Pain},
year = {2025},
doi = {10.1177/17448069251314857}
}
EUVIMED